Abstract 199P
Background
Atezolizumab plus bevacizumab was approved in 2022 in Vietnam as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC.
Methods
Retrospective study, single-arm, single center on 31 patients diagnosed with advanced HCC defined as the Barcelona clinic liver cancer staging system (BCLC) stage B was unsuitable or failed with local interventions or BCLC stage C, indicated systemic therapy with Bevacizumab combined with Atezolizumab regimen at K Hospital from May 2022 to March 2023. The outcomes included pooled overall response (OR), complete response (CR), partial response (PR), median overall survival (mOS), median progression-free survival (mPFS), and adverse events (AEs).
Results
The response rate was 41.9%, median progressive-free survival was 5 months and median overall survival was 15.5 months. Grade 3 and 4 toxicities occurred in 9.7% patients including hypertension, increased liver enzymes and thrombocytopenia. Twenty-three studies, comprising 3168 patients, were enrolled. The pooled OR, CR, and PR rates of the long-term (more than six weeks) therapy response based on Response Evaluation Criteria in Solid Tumors (RECIST) were 26%, 2%, and 23%, respectively. The pooled OR, CR, and PR rates of the short-term (six weeks) therapeutic response evaluated with RECIST were 13%, 0%, and 15%, respectively. The pooled mOS and mPFS were 14.7 months and 6.66 months, respectively. During the treatment, 83% and 30% of patients experienced any grade AEs and grade 3 and above AEs, respectively.
Conclusions
Bevacizumab-Atezolizumab regimen is effective and well-tolerated in patients with hepatocellular carcinoma in Vietnam. Atezolizumab in combination with bevacizumab showed good efficacy and tolerability in the treatment of advanced HCC. Compared with short-term, non-first-line, and low-dose therapy, atezolizumab plus bevacizumab in long-term, first-line, and standard-dose treatment for advanced HCC showed a better tumor response rate.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.